Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes-A Potential Alternative to Current Anti-Inflammatory Drugs?

J. Hrdý, L. Súkeníková, P. Petrásková, O. Novotná, D. Kahoun, M. Petříček, A. Chroňáková, K. Petříčková,

. 2020 ; 8 (5) : . [pub] 20200425

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20019287

Grant support
No. 17-30091A Agentura Pro Zdravotnický Výzkum České Republiky
NV17-30091A MZ0 CEP Register

Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various, sometimes serious, side effects. Small secondary metabolites produced by various microbes represent an attractive alternative as future anti-inflammatory drug leads. Compared to current drugs, they are cheaper, can often be administered orally, but still can keep a high target-specificity. Some compounds produced by actinomycetes or fungi have already been used as immunomodulators-tacrolimus, sirolimus, and cyclosporine. This work documents strong anti-inflammatory features of another secondary metabolite of streptomycetes-manumycin-type polyketides. We compared the effect of four related compounds: manumycin A, manumycin B, asukamycin, and colabomycin E on activation and survival of human monocyte/macrophage cell line THP-1. The anti-cancer effect of manucycine A has been demonstrated; the immunomodulatory capacities of manumycin A are obvious when using micromolar concentrations. The application of all four compounds in 0.25-5 μM concentrations leads to efficient, concentration-dependent inhibition of IL-1β and TNF expression in THP-1 upon LPS stimulation, while the three latter compounds show a significantly lower pro-apoptotic effect than manumycin A. We have demonstrated the anti-inflammatory capacity of selected manumycin-type polyketides.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019287
003      
CZ-PrNML
005      
20210310105922.0
007      
ta
008      
201103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/microorganisms8050621 $2 doi
035    __
$a (PubMed)32344935
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hrdý, Jiří $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 116 36 Prague, Czech Republic.
245    10
$a Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes-A Potential Alternative to Current Anti-Inflammatory Drugs? / $c J. Hrdý, L. Súkeníková, P. Petrásková, O. Novotná, D. Kahoun, M. Petříček, A. Chroňáková, K. Petříčková,
520    9_
$a Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various, sometimes serious, side effects. Small secondary metabolites produced by various microbes represent an attractive alternative as future anti-inflammatory drug leads. Compared to current drugs, they are cheaper, can often be administered orally, but still can keep a high target-specificity. Some compounds produced by actinomycetes or fungi have already been used as immunomodulators-tacrolimus, sirolimus, and cyclosporine. This work documents strong anti-inflammatory features of another secondary metabolite of streptomycetes-manumycin-type polyketides. We compared the effect of four related compounds: manumycin A, manumycin B, asukamycin, and colabomycin E on activation and survival of human monocyte/macrophage cell line THP-1. The anti-cancer effect of manucycine A has been demonstrated; the immunomodulatory capacities of manumycin A are obvious when using micromolar concentrations. The application of all four compounds in 0.25-5 μM concentrations leads to efficient, concentration-dependent inhibition of IL-1β and TNF expression in THP-1 upon LPS stimulation, while the three latter compounds show a significantly lower pro-apoptotic effect than manumycin A. We have demonstrated the anti-inflammatory capacity of selected manumycin-type polyketides.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Súkeníková, Lenka $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 116 36 Prague, Czech Republic.
700    1_
$a Petrásková, Petra $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 116 36 Prague, Czech Republic.
700    1_
$a Novotná, Olga $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 116 36 Prague, Czech Republic.
700    1_
$a Kahoun, David $u Faculty of Science, University of South Bohemia, 370 05 České Budějovice, Czech Republic.
700    1_
$a Petříček, Miroslav $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 116 36 Prague, Czech Republic.
700    1_
$a Chroňáková, Alica $u Institute of Soil Biology, Biology Centre Academy of Sciences of the Czech Republic, 370 05 České Budějovice, Czech Republic.
700    1_
$a Petříčková, Kateřina $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 116 36 Prague, Czech Republic. Faculty of Science, University of South Bohemia, 370 05 České Budějovice, Czech Republic.
773    0_
$w MED00198767 $t Microorganisms $x 2076-2607 $g Roč. 8, č. 5 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32344935 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20210310105918 $b ABA008
999    __
$a ind $b bmc $g 1586065 $s 1109485
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c 5 $e 20200425 $i 2076-2607 $m Microorganisms $n Microorganisms $x MED00198767
GRA    __
$a No. 17-30091A $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NV17-30091A $p MZ0
LZP    __
$a Pubmed-20201103

Find record

Citation metrics

Archiving options